Introduction
Clostridium difficile is the most common cause of infectious diarrhoea in hospitalised patients [1] , in the United States (US) costing more than USD 3 billion (EUR 2.8 billion) annually [2] . Infection occurs following ingestion of C. difficile. Exposure to agents that alter the gut microflora, often antibiotics, [3] is normally required, but about half of the cases with community-onset C. difficile infection (CDI) may not have received recent antibiotics [4] . Since 2003, rates of healthcare-related CDI have escalated worldwide, with a new hyper-virulent strain of C. difficile (PCR ribotype 027) responsible for outbreaks of severe disease in North America and Europe [5] . Following the first detection of ribotype 027 in Australia in 2008 [6] , there have been two known clusters of ribotype 027 infection that occurred in Melbourne and Sydney in 2010 [7] . However, the strain has not become endemic in Australia; it is unclear whether this is because of early recognition and subsequent prevention of large scale spread and/or because of relatively conservative antimicrobial prescribing policies, for example low use of fluoroquinolones to which ribotype 027 is resistant [5, 8] . Rates of community-associated CDI have also increased in North America and Europe [9, 10] and community-associated CDI is estimated to be responsible for more than one third of all CDI cases. Patients with community-associated CDI tend to be younger, less likely to have been exposed to antibiotics, and have fewer co-morbidities than patients with healthcareacquired infection [11] .
Australian States and Territories currently operate separate, primarily hospital-based, mandatory surveillance for CDI as part of hospital accreditation. All Australian states have seen a significant increase in hospital-identified CDI incidence since mid-2011, which is unlikely to be completely explained by recent changes to more sensitive molecular diagnostic methods or increased awareness of CDI and testing. The proportion of recent CDI cases defined as communityassociated has also increased throughout Australia [12] . A recent report on CDI in Tasmania concluded that the observed increase in CDI was most likely due to acquisition in the community [13] .
In October and November 2011, a large cluster of an apparently new (to Australia) ribotype was identified by a reference laboratory in Western Australia (WA) in isolates from New South Wales (NSW). At about the same time, reports emerged from Victoria of cases of CDI initially identified as putative ribotype 027 with the GeneXpert system (Cepheid, Sunnyvale, CA), but actually matching the NSW ribotype [14] . Subsequent interrogation of the WA laboratory database identified further CDIs due to the same ribotype (eventually identified as ribotype 244).
Investigation of the 12 ribotype 244 cases in Victoria, demonstrated that the strain was associated with more severe disease, 58% had severe disease compared to 25% of cases with non-ribotype 244, non-ribotype-027 strains, and increased mortality, 42% 30-day mortality vs 0% [14] . Whole genome sequencing of one of the 12 ribotype 244 isolates showed it to be from the same clade as ribotype 027, but genetically distinct from ribotype 027 [14] . Ribotype 244 cases have also been identified in New Zealand: In a case-control study, 10 ribotype 244 CDI cases were more likely to develop severe colitis than 20 age-and sex-matched controls with CDI with other ribotypes [15] .
In this report, we describe the secular trends in the prevalence of hospital-identified CDI in WA from 2010 to 2012, and in particular CDI due to ribotype 244. We use whole genome sequencing of ribotype 244 isolates recovered in WA and two other states to investigate strain clonality. Lastly, we report international spread of this ribotype.
Methods

Epidemiology
CDI incidence data were obtained from the WA hospital CDI surveillance programme from January 2010 to December 2012 inclusive. In WA, surveillance for CDI has been mandatory since January 2010 for all public metropolitan, regional and integrated district hospitals, and private hospitals funded to provide care to public patients. These hospitals were also encouraged to submit all C. difficile-positive faecal samples for PCR ribotyping from January 2010 onwards, with increasing numbers participating during 2010 and 2011, such that all hospitals were providing samples by October 2011.
A CDI case was defined as a case of diarrhoea, i.e. unformed stool taking the shape of its container, meeting the following criteria: the stool sample yielded a positive result in a laboratory assay for C. difficile toxin A and/or B, or a toxin-producing strain of C. difficile was detected in the stool sample by culture or other means. Cases were only included once in an eightweek period; repeat samples from the same patient after eight weeks were considered a new infection. Patients younger than two years were excluded.
CDI was reported from patients attending any area of a hospital, i.e. all inpatient wards and units (including psychiatric, rehabilitation and aged care admissions) and emergency and outpatient departments (including haemodialysis and day surgery units); as such, reporting reflected the total burden of CDI on a hospital and sampled the surrounding community, as the reported cases included disease with both healthcare-and community onset. Data on recent healthcare facility exposure were available on cases identified at metropolitan hospitals (accounting for the majority of cases), allowing these CDI cases to be classified according to the place of probable exposure as described by Kuijper et al. [16] and recent US guidelines [17] : CDI was classified by location of onset, as healthcare facility (HCF) onset or as community-onset, and by the timing relative to any previous healthcare exposure. CDI onset more than 48 hours after HCF admission and within four weeks of discharge was denoted HCF-associated, onset between four and 12 weeks post-discharge was denoted indeterminate/unknown (whether communityonset or HCF-onset), and onset more than 12 weeks following last HCF exposure was denoted communityassociated. HCF-associated CDI rates are reported per 10,000 bed-days. As identified community-associated cases were only a subset of all community-associated cases (cases presenting to primary care facilities and smaller hospitals were not included), simple counts of community-associated cases per quarter are presented. Severe CDI was defined as an episode of CDI with one or more signs of severe colitis [18] .
PCR ribotyping and toxin gene profiling
Crude bacterial template DNA for toxin profiling was prepared by resuspension of cells in a 5% (wt/vol) solution of Chelex-100 resin (Sigma-Aldrich, Castle Hill, NSW, Australia). All isolates were screened by PCR for the presence of the toxin A (tcdA) and toxin B (tcdB) genes [19] and the binary toxin (cdtA and cdtB) genes [20] , and for changes in the repeating region of tcdA [21] . PCR ribotyping was performed as previously described [22] . PCR ribotyping banding patterns were identified by comparison with a reference library consisting of reference strains from the European Centre for Disease Prevention and Control (ECDC)-Brazier collection [23] Sequence reads were analysed and assembled using a pipeline developed specifically for bacterial genomes: Each isolate was mapped using Stampy v1.0.11 (without Burrows-Wheeler Aligner pre-mapping, using an expected substitution rate of 0.01) [25] to the C. difficile 630 reference genome (GenBank: AM180355.1), CD630 [26] . Single nucleotide variants (SNVs) were identified across all mapped non-repetitive core genome sites using the SAMtools (version 0.1.12-10) mpileup command with the extended base-alignment quality flag, after parameter tuning based on bacterial sequences. A consensus of at least 75% was required to support a SNV, and calls were required to be homozygous under a diploid model. Only SNVs supported by at least five reads, including one in each direction, were accepted. Sequence reads were also assembled de novo using Velvet [27] , run with the Velvet Optimiser. De novo assemblies were used to determine in silico multilocus sequence types (MLST).
Sequences from the ribotype 244 isolates were compared with available fully-sequenced reference isolates, with sequences from a reference laboratory collection (CDRN), and a collection of clinical isolates from Oxfordshire, UK, representing all five C. difficile clades [28] . As ribotype 244 has been shown to be from Clade 2 [14] , we included previously sequenced Clade 2 strains from the Oxfordshire clinical collection, including example ST1 strains (ribotype 027) and all available ST41, ST47, ST67, ST97 and ST114 strains.
Maximum likelihood phylogenetic trees were drawn based on variable sites called across all sequences, using PhyML [29] with a Hasegawa, Kishino and Yano (HKY) substitution model. Ribotype 244 sequences were analysed using BEAST 1.7.5 [30] to generate a time-scaled phylogenetic tree and estimate the date of the most recent common ancestor of the outbreak strains. After identifying variable sites between the sequences, any variants clustered within 323 sites (the mean recombination insert size for Clade 2 isolates in a previous analysis [28] ) were masked to remove these likely recombination events. To reduce the time for computation, any uncalled bases at otherwise invariant sites were assumed to be the same as the reference. We assumed a constant population size and a constant molecular clock at a previously estimated rate of 3.2 × 10 − 7 substitutions per site per year [28] . Data from two convergent chains, initiated from different starting values, each of 10,000,000 iterations, were combined after discarding the first 100,000 iterations as burn-in. A HKY substitution model was used with empiric base frequencies.
Results
Epidemiology of Clostridium difficile infection in Western Australia
During the three years of surveillance from January 2010 to December 2012 in Western Australia, there were a total of 2,061 hospital-identified CDI cases with a peak of 294 cases in quarter 1 2012 (Figure 1 ). Of 1,681 cases reported by metropolitan hospitals (where data on recent healthcare facility exposure was recorded), 1,086 (65%) cases were HCF-associated, 478 (28%) community-associated and 117 (7%) indeterminate/unknown. Overall HCF-associated CDI incidence increased markedly in mid-2011 from 2.5/10,000 bed-days in the second quarter (April-June) to a peak at over 4.5/10,000 bed-days in the first quarter of 2012 (January-March) before declining over the next two CDI: Clostridium difficile infection. CDI was reported for patients attending any area of a hospital, i.e. all inpatient, emergency and outpatient departments. As such, reporting reflected the burden of CDI on a hospital and the surrounding community, as the reported cases included healthcare and community onset disease.
quarters, and then increasing again in the last quarter of 2012 (Figure 2 ). Trends in community-associated CDI rates followed the rates of healthcare-associated cases closely.
Ribotype 244 epidemiology in Western Australia
In Of the 25 ribotype 244 cases, 13 were female, 14 were 65 years or older, 14 presented at hospital emergency departments or were outpatients, and 14 presented at non-tertiary or community hospitals. Using surveillance definitions, 18 were community-onset (14 were community-associated infections and four were both community-onset and HCFA), and seven were both sequence assembly and analysis approaches used. It is likely that, despite both belonging to the same clade, the current ribotype 244 is separated from ribotype 027 by hundreds/thousands of years given rates of C. difficile evolution [5, 28, 31] .
Ribotype 244 outbreak phylogeny
All 15 Australian ribotype 244 isolates were within 16 observed SNVs of each other, and all but one isolate were within eight SNVs, including a cluster of seven cases from three different states which were within four SNVs of each other. We compared the phylogenetic relationship between the outbreak isolates using a time-scaled Bayesian phylogeny ( Figure 5 Interestingly, a ribotype 244 isolate held in the CDRN reference laboratory, from a patient in Southampton, UK, fell within the diversity of the Australian outbreak strains. Further epidemiological investigation initiated as a result of the sequencing data revealed that the UK patient had returned from Australia (Brisbane, Queensland) three weeks before the onset of diarrhoeal symptoms; this person had spent ca three Tips are positioned by sampling date and coloured by Australian state of origin; grey: related UK and US strains; maroon: a closely related UK strain, as the patient had recently returned from Brisbane, Queensland. Tree branches are coloured by the posterior clade probability for each node. As indicated in the legend, blue branches are strongly supported by the sequence data and red branches more weakly supported. Nodes with posterior probabilities greater than 50% are annotated with the posterior support as a percentage. The terminal branches with low support at the bottom of the tree indicate that these isolates are similar (within four observed SNVs), consistent with a point source, but the exact ordering of their ancestry is not certain from the data.
months in Australia in late 2011. The patient had not made any visits to hospitals or GPs while in Australia nor stayed with anyone who was ill or on antibiotics. One relative they visited worked in a care home. The patient remained well until they required antibiotics for an unrelated complaint after returning to the UK. They developed diarrhoea shortly thereafter and were diagnosed with CDI within three weeks of return to the UK. The only risk factors for CDI identified in the UK patient were age over 65 years and recent antibiotic use. Two ribotype 244 isolates from the US, one previously identified as ribotype 244 in [32] , and a ribotype 321 isolate from Oxfordshire, UK were closely related to, but distinct from, the Australian ribotype 244 outbreak isolates ( Figure 5 ). There are no reports of ribotype 321 in Australia. Only two ribotype 321 isolates have been identified by the UK CDRN reference laboratory to date, the Oxfordshire clinical strain and a food research centre isolate from Ireland in 2010.
Discussion
Here we describe a clonal outbreak of ribotype 244 throughout Australia, against a background of rising CDI incidence. Isolates originating from four states across Australia were genetically closely related without any evidence of geographical or temporal structure in their phylogenetic relationships, and over half of cases occurred without recent healthcare exposure, suggesting a possible community-based point source dispersed nationally. The majority of ribotype 244 cases were community-onset and many were detected in patients younger than 65 years and in those who presented to hospital emergency departments, rather than in hospital inpatients. Notably, by using the discriminatory power of WGS, we were also able to identify spread of the outbreak strain to the UK via a returning traveller. Since the end of 2012 there has been a decline in new cases of ribotype 244 in WA, supporting the suggestion that the cases in 2011/12 represented an outbreak followed by some ongoing transmission.
In contrast to Europe and North America, Australia has not seen large epidemics with C. difficile ribotype 027 despite at least two introductions [6, 7] ; it is possible that relatively conservative antimicrobial prescribing practices [8] and/or the geographical isolation of Australia have been responsible [33] . Despite the limited numbers of ribotype 244 cases seen, this outbreak does demonstrate that there is potential for epidemic spread in Australia too. Although ribotype 244 only accounted for 3% of all cases in WA, the outbreak occurred against a background of rising CDI incidence. Since mandatory reporting was introduced three years ago, rates of CDI in WA have more than doubled ( Figure  2 ). Australia-wide increases in CDI incidence could be due to a number of factors. Increased awareness of CDI may have increased testing [34] ; however, a 25% increase in laboratory testing in WA is very unlikely to account for the observed rise in CDI cases. Similarly, more sensitive testing methods could have resulted in increased reported incidence, with many laboratories changing from enzyme immunoassay testing, with ca 60-85% sensitivity, to nucleic acid amplification tests, with more than 95% sensitivity (but decreased specificity) [35] . Changes in laboratory testing during late 2010 may have accounted for some of the increase in measured CDI rates in WA in quarters 3 and 4 of 2010. However, such potential laboratory ascertainment bias does not explain the increases in CDI rates recorded from quarter 3 onwards in 2011.
The introduction of new C. difficile strains, including ribotype 244, alongside rises in the incidence of established strains, underlies the observed increased incidence of CDI overall. Two snap-shot surveys from the Australian Commission on Safety and Quality in Healthcare, the first in October and November 2010, and the second in October and November 2012, described the ribotypes of C. difficile circulating in Australia. Representative samples of 330 and 556 isolates, respectively, predominantly from hospital laboratories, were collected from all Australian states and ribotyped. The most common ribotypes in 2010 were 014/020 (30%), followed by 002 (11%); a ribotype could not be assigned to 53% of isolates. By 2012, ribotypes 014/020 and 002 still accounted for 25% and 10% of CDI, respectively, but significant increases in the proportion of cases due to ribotypes 056, 070, 054, 015, 017, 053 and 244 were seen compared with 2010, with each of these ribotypes accounting for between 3% and 6% of cases (data not shown).
There now appears to be seasonality to CDI incidence in Australia; this has been demonstrated in other countries [36] , but has been assumed to be due to healthcare-associated CDI following increased antibiotic treatment of winter-associated severe respiratory tract infections. By contrast, much of the increase in Australian CDI incidence has been due to communityassociated CDI cases with no previous contact with the hospital system [12, 13] . The most likely explanation for this is the combination of community-associated strains, and the seasonal peak in antimicrobial prescriptions in the community, following respiratory tract infections [37] . A limitation of surveillance data used in our study and the surveys described above, is that they were hospital-based. Although cases tested as outpatients were included, patients tested by general practitioners working outside of hospitals were not. As such the surveillance may underestimate the proportion of total CDI accounted for by strains predominantly causing community-associated disease.
The recent emergence of ribotype 244 in surveillance data is in keeping with our estimated date (2009) for the most recent common ancestor of the majority of the outbreak strains. If a point source was the explanation for the outbreak we might have expected the most recent common ancestor to be closer in time to the beginning of the outbreak, i.e. around 2011, and fewer than the observed eight SNVs separating the majority of the outbreak strains. However it is also possible that some within-host/within-reservoir diversity existed in the source of the outbreak before the first cases, analogous to the within-host diversity seen in some CDI [28, 38] . A single strain from NSW was more diverse, and may represent a separate introduction, or pre-existing diversity in the source of the outbreak.
Although ribotype 244 strains share some features with ribotype 027, WGS suggests these strains are substantially different at a whole genome level [14] , confirmed in this study and in keeping with a previous description based on microarray data [39] . Ribotype 244 strains produce toxins A, B and binary toxin, are susceptible to fluoroquinolones and associated with more severe disease [14, 15] .
We have demonstrated that ribotype 244 CDI was significantly more likely to be community-associated than other ribotypes, 56% of ribotype 244 cases were community-associated, compared with 28% of other ribotypes. In keeping with our data, there is also some evidence that cases from New Zealand were more likely to be community-associated than controls, 50% of cases vs 15% of controls (p = 0.08) [15] . In another case-control study in Victoria, Australia, proportionally more ribotype 244 cases were community-associated (four of 12) than non-ribotype 244 controls (six of 24), however this was not statistically significant (p = 0.72) [14] . The relative excess of community-associated ribotype 244 CDI suggests a possible community source or reservoir. The nature of this source is unknown but is unlikely to be spores shed from recently hospitalised patients following discharge as this strain is different from those circulating in Australian healthcare facilities (predominantly ribotypes 014/020 and 002). One potential reservoir of infection in the community is animals [40] . C. difficile is known to colonise or infect animals and outside of Australia, the predominant animal strain is ribotype 078, commonly isolated from pigs and cattle [41] . This strain is responsible for increasing rates of community-acquired CDI in Europe [42, 43] , suggesting that a zoonosis exists, however transmission of ribotype 244 from animals has not been observed to date. Contaminated food represents another potential source. C. difficile contamination of food has been previously reported in retail meat products in the US [44, 45] , in ready-to-eat salads/vegetables in Scotland [46] and France [47] , and in vegetables and seafood in Canada [48, 49] The numbers of ribotype 244 cases being seen in Australia currently, although high compared with previous surveys, do not completely account for the increased CDI rates seen over the past two years. Ribotypes circulating previously account for many cases, e.g. 014/020, 002, 056, and 054 (Table) . However other new ribotypes of C. difficile may have been introduced into the country recently or emerged locally. We already have preliminary evidence of this in a significant number of infections with ribotype 251 C. difficile, another strain that has not been found in Australia previously (data not shown). Our data demonstrate that new strains causing CDI are an ongoing threat in Australia and worldwide, with rapid potential for spread as has been seen with ribotype 027 [5] . Active surveillance of CDI cases [50, 51] alongside strain typing and rapid sequencing [52] is needed to identify and control emerging lineages.
